Ammonia metabolism and hyperammonemic disorders

Advances in Clinical Chemistry

Volumn 67, Issue , 2014, Pages 73-150

  Walker, Valerie ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Ammonia toxicity; Anaplerosis; Glutamine; Hepatic encephalopathy; Hyperammonemia; Malate aspartate shuttle; Phenylbutyrate; Urea cycle; Urea cycle defects

Indexed keywords

AMMONIA; ARGININE; UREA; VALPROIC ACID;

ANIMAL; BRAIN; CELL MEMBRANE; GENETICS; HUMAN; HYPERAMMONEMIA; HYPERINSULINISM; LIVER; LIVER DISEASE; METABOLISM; MICROBIOLOGY; PYRUVATE CARBOXYLASE DEFICIENCY DISEASE; SYNDROME; TRANSPORT AT THE CELLULAR LEVEL; URINARY TRACT DISEASE;

AMMONIA; ANIMALS; ARGININE; BIOLOGICAL TRANSPORT; BRAIN; CELL MEMBRANE; HUMANS; HYPERAMMONEMIA; HYPERINSULINISM; LIVER; LIVER DISEASES; PYRUVATE CARBOXYLASE DEFICIENCY DISEASE; SYNDROME; UREA; UROLOGIC DISEASES; VALPROIC ACID;

EID: 84921927301     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/bs.acc.2014.09.002     Document Type: Chapter

References (289)

1. Meijer A.J., Lamers W.H., Chamuleau R.A.F.M. Nitrogen metabolism and ornithine cycle function. Physiol. Rev. 1990, 70(3):701-748.
2. Painter P.C., Cope J.Y., Smith J.L. Appendix: reference intervals, clinical chemistry and toxicology. Tietz Textbook of Clinical Chemistry 1994, 2175-2211. W.B. Saunders Company, Philadelphia. second ed. C.A. Burtis, E.R. Ashwood (Eds.).
3. Cooper A.J.L., Lai J.C. Cerebral ammonia metabolism in normal and hyperammonemic rats. Neurochem. Pathol. 1987, 6(1-2):67-95.
4. Taylor-Robinson S.D., Sargentoni J., Mallalieu R.J., Bell J.D., Bryant D.J., Coutts G.A., et al. Cerebral phosphorus-31 magnetic resonance spectroscopy in patients with chronic hepatic encephalopathy. Hepatology 1994, 20(5):1173-1178.
5. Butterworth R.F. Pathophysiology of hepatic encephalopathy: a new look at ammonia. Metab. Brain Dis. 2002, 17(4):221-227.
6. Bachmann C., Braissant O., Villard A.-M., Boulat O., Henry H. Ammonia toxicity to the brain and creatine. Mol. Genet. Metab. 2004, 81(Suppl. 1):S52-S57.
7. Gropman A.L., Summar M., Leonard J.V. Neurological implications of urea cycle disorders. J. Inherit. Metab. Dis. 2007, 30(6):865-869.
8. Zwingmann C. Nuclear magnetic resonance studies of energy metabolism and glutamine shunt in hepatic encephalopathy and hyperammonemia. J. Neurosci. Res. 2007, 85(15):3429-3442.
9. Iversen P., Sørensen M., Bak L.K., Waagepetersen H.S., Vafaee M.S., Borghammer P., et al. Low cerebral oxygen consumption and blood flow in patients with cirrhosis and an acute episode of hepatic encephalopathy. Gastroenterology 2009, 136(3):863-871.
10. Brusilow S.W., Koehler R.C., Traystman R.J., Cooper A.J.L. Astrocyte glutamine synthetase: importance in hyperammonemic syndromes and potential target for therapy. Neurotherapeutics 2010, 7(4):452-470.
11. 13N-ammonia metabolites in blood. Metab. Brain Dis. 2010, 25(1):49-56.
12. Goldbecker A., Buchert R., Berding G., Bokemeyer M., Lichtinghagen R., Wilke F., et al. Blood-brain barrier permeability for ammonia in patients with different grades of liver fibrosis is not different from healthy controls. J. Cereb. Blood Flow Metab. 2010, 30(7):1384-1393.
13. Gropman A. Brain imaging in urea cycle disorders. Mol. Genet. Metab. 2010, 100(Suppl. 1):S20-S30.
14. Braissant O., McLin V.A., Cudalbu C. Ammonia toxicity to the brain. J. Inherit. Metab. Dis. 2013, 36(4):595-612.
15. Dam G., Keiding S., Munk O.L., Ott P., Vilstrup H., Bak L.K., et al. Hepatic encephalopathy is associated with decreased cerebral oxygen metabolism and blood flow, not increased ammonia uptake. Hepatology 2013, 57(1):258-265.
16. 13C NMR spectroscopy applications to brain energy metabolism. Front. Neuroenergetics 2013, 5:9.
17. 13C magnetic resonance spectroscopic imaging. J. Cereb. Blood Flow Metab. 2012, 32(8):1508-1514.
18. Mishkovsky M., Comment A., Gruetter R. In vivo detection of brain Krebs cycle intermediate by hyperpolarized magnetic resonance. J. Cereb. Blood Flow Metab. 2012, 32(12):2108-2113.
19. Tofteng F., Jorgensen L., Hansen B.A., Ott P., Kondrup J., Larsen F.S. Cerebral microdialysis in patients with fulminant hepatic failure. Hepatol. 2002, 36(6):1333-1340.
20. Tofteng F., Hauerberg J., Hansen B.A., Pedersen C.B., Jørgensen L., Larsen F.S. Persistent arterial hyperammonemia increases the concentration of glutamine and alanine in the brain and correlates with intracranial pressure in patients with fulminant hepatic failure. J. Cereb. Blood Flow Metab. 2006, 26(1):21-27.
21. Curthoys N.P. Role of mitochondrial glutaminase in rat renal glutamine metabolism. J. Nutr. 2001, 131(Suppl. 9):2491S-2495S.
22. Hägglund M.G.A., Sreedharan S., Nilsson V.C.O., Shaik J.H.A., Almkvist I.M., Bäcklin S., et al. Identification of SLC38A7 (SNAT7) protein as a glutamine transporter expressed in neurons. J. Biol. Chem. 2011, 286(23):20500-20511.
23. + transporters in renal acid-base transport. Am. J. Physiol. Renal Physiol. 2011, 300(1):F11-F23.
24. Cooper A.J.L. The role of glutamine synthetase and glutamate dehydrogenase in cerebral ammonia homeostasis. Neurochem. Res. 2012, 37(11):2439-2455.
25. Lichter-Konecki U. Profiling of astrocyte properties in the hyperammonaemic brain: shedding new light on the pathophysiology of the brain damage in hyperammonaemia. J. Inherit. Metab. Dis. 2008, 31(4):492-502.
26. Desjardins P., Du T., Jiang W., Peng L., Butterworth R.F. Pathogenesis of hepatic encephalopathy and brain edema in acute liver failure: role of glutamine redefined. Neurochem. Int. 2012, 60(7):690-696.
27. Kobayashi K., Saheki T., Song Y.Z. Citrin deficiency. GeneReviews™ [Internet] 1993-2013, (2005 September, updated 2014 July), University of Washington, Seattle, WA, Available from:, (accessed 06.10.14). http://www.ncbi.nlm.nih.gov/books/NBK1181/, R.A. Pagon, M.P. Adam, H.H. Ardinger (Eds.).
28. Walker V. Severe hyperammonaemia in adults not explained by liver disease. Ann. Clin. Biochem. 2012, 49(3):214-228.
29. + in human plasma, isotonic salt solutions and water at 37°C. Clin. Chim. Acta 1998, 273(1):43-58.
30. Cooper A.J.L., Plum F. Biochemistry and physiology of brain ammonia. Physiol. Rev. 1987, 67(2):440-519.
31. Marcaggi P., Coles J.A. Ammonium in nervous tissue: transport across cell membranes, fluxes from neurons to glial cells, and role in signalling. Prog. Neurobiol. 2001, 64(2):157-183.
32. Litman T., Søgaard R., Zeuthen T. Ammonia and urea permeability of mammalian aquaporins. Handbook, Exp. Pharmacol. 2009, 190:327-358.
33. Waterlow J.C. The mysteries of nitrogen balance. Nutr. Res. Rev. 1999, 12(1):25-54.
34. Young V.R., El-Khoury A.E., Raguso C.A., Forslund A.H., Hambraeus L. Rates of urea production and hydrolysis and leucine oxidation change linearly over widely varying protein intakes in healthy adults. J. Nutr. 2000, 130(4):761-766.
35. Summerskill W.H.J., Wolpert E. Ammonia metabolism in the gut. Am. J. Clin. Nutr. 1970, 23(5):633-639.
36. Windmueller H.G., Spaeth A.E. Uptake and metabolism of plasma glutamine by the small intestine. J. Biol. Chem. 1974, 249(16):5070-5079.
37. Paglia D.E., Valentine W.N., Nakatani M., Brockway R.A. AMP deaminase as a cell-age marker in transient erythroblastopenia of childhood and its role in the adenylate economy of erythrocytes. Blood 1989, 74(6):2161-2165.
38. Sabina R.L., Holmes E.W. Myoadenylate deficiency. The Metabolic & Molecular Bases of Inherited Disease 2001, 2627-2638. McGraw-Hill, New York. eighth ed. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
39. Schultz V., Lowenstein J.M. Purine nucleotide cycle. Evidence for the occurrence of the cycle in brain. J. Biol. Chem. 1976, 251(2):485-492.
40. Wilkinson D.J., Smeeton N.J., Watt P.W. Ammonia metabolism, the brain and fatigue; revisiting the link. Prog. Neurobiol. 2010, 91(3):200-219.
41. Meyer R.A., Dudley G.A., Terjung R.L. Ammonia and IMP in different skeletal muscle fibers after exercise in rats. J. Appl. Physiol. 1980, 49(6):1037-1041.
42. Schultz V., Lowenstein J.M. The purine nucleotide cycle. J. Biol. Chem. 1978, 253(6):1938-1943.
43. Aragón J.J., Lowenstein J.M. The purine nucleotide cycle: comparison of the levels of citric acid cycle intermediates with the operation of the purine nucleotide cycle in rat skeletal muscle during exercise and recovery from exercise. Eur. J. Biochem. 1980, 110(2):371-377.
44. Canela E.I., Ginesta I., Franco R. Simulation of the purine nucleotide cycle as an anaplerotic process in skeletal muscle. Arch. Biochem. Biophys. 1987, 254(1):142-155.
45. van de Poll M.C.G., Soeters P.B., Deutz N.E.P., Fearon K.C.H., Dejong C.H.C. Renal metabolism of amino acids: its role in interorgan amino acid exchange. Am. J. Clin. Nutr. 2004, 79(2):185-197.
46. 13N]ammonia in rat lung. Neurochem. Int. 2005, 47(1-2):103-118.
47. 13N-labeled glutamate, alanine, and glutamine(amide) in rat liver. J. Biol. Chem. 1988, 263(25):12268-12273.
48. Brusilow S.W., Horwich A.L. Urea cycle enzymes. The Metabolic & Molecular Bases of Inherited Disease 2001, 1909-1963. McGraw-Hill, New York. eighth ed. C.R. Scriver, D. Beaudet, W.S. Sly, D. Valle (Eds.).
49. Häberle J. Clinical practice: the management of hyperammonemia. Eur. J. Pediatr. 2011, 170(1):21-34.
50. Takiguchi M., Mori M. Transcriptional regulation of genes for ornithine cycle enzymes. Biochem. J. 1995, 312(3):649-659.
51. Nakagawa T., Guarente L. Urea cycle regulation by mitochondrial sirtuin, SIRT5. Aging 2009, 1(6):578-581.
52. Christoffels V.M., van den Hoff M.J.B., Lamers M.C., van Roon M.A., de Boer P.A.J., Moorman A.F.M., et al. The upstream regulatory region of the carbamoyl-phosphate synthetase 1 gene controls its tissue-specific, developmental, and hormonal regulation in vivo. J. Biol. Chem. 1996, 271(49):31243-31250.
53. Uchiyama C., Mori M., Tatibana M. Subcellular localization and properties of N-acetylglutamate synthase in rat small intestinal mucosa. J. Biochem. 1981, 89(6):1777-1786.
54. Heibel S.K., Lopez G.Y., Panglao M., Sodha S., Mariño-Ramírez L., Tuchman M., et al. Transcriptional regulation of N-acetylglutamate synthase. PLoS One 2012, 7(2):e29527.
55. Schimke R.T. Differential effects of fasting and protein-free diets on levels of urea cycle enzymes in rat liver. J. Biol. Chem. 1962, 237(6):1921-1924.
56. Schimke R.T. Studies on factors affecting the levels of urea cycle enzymes in rat liver. J. Biol. Chem. 1963, 238(3):1012-1018.
57. Ryall J.C., Quantz M.A., Shore G.C. Rat liver and intestinal mucosa differ in the developmental pattern and hormonal regulation of carbamoyl-phosphate synthetase 1 and ornithine carbamoyl transferase gene expression. Eur. J. Biochem. 1986, 156(3):453-458.
58. Morris S.M. Regulation of enzymes of urea and arginine synthesis. Annu. Rev. Nutr. 1992, 12:81-101.
59. Meijer A.J., Lof C., Ramos I.C., Verhoven A.J. Control of ureogenesis. Eur. J. Biochem. 1985, 148(1):189-196.
60. Erez A., Nagamani S.C.S., Lee B. Argininosuccinate lyase deficiency-argininosuccinic aciduria and beyond. Am. J. Med. Genet. C Semin. Med. Genet. 2011, 157C(1):45-53.
61. Erez A., Nagamani S.C.S., Schelochkov O.A., Premkumar M.H., Campeau P.M., Chen Y., et al. Requirement of argininosuccinate lyase for systemic nitric oxide production. Nat. Med. 2011, 17(12):1619-1626.
62. Davis P.K., Wu G. Compartmentation and kinetics of urea cycle enzymes in porcine enterocytes. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 1998, 119(3):527-537.
63. Luiking Y.C., Ten Have G.A.M., Wolfe R.R., Deutz N.E.P. Arginine de novo and nitric oxide production in disease states. Am. J. Physiol. Endocrinol. Metab. 2012, 303(10):E1177-E1189.
64. Haines R.J., Pendleton L.C., Eichler D.C. Argininosuccinate synthase: at the center of arginine metabolism. Int. J. Biochem. Mol. Biol. 2011, 2(1):8-23.
65. Camacho J., Rioseco-Camacho N. Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome. GeneReviews™ [Internet] 1993-2013, (2012 May 31), University of Washington, Seattle, WA, Available from:, (accessed 10.10.14). http://www.ncbi.nlm.nih.gov/books/NBK97260/, R.A. Pagon, M.P. Adam, H.H. Ardinger (Eds.).
66. McKenna M.C., Waagepetersen H.S., Schousboe A., Sonnewald U. Neuronal and astrocytic shuttle mechanisms for cytosolic-mitochondrial transfer of reducing equivalents: current evidence and pharmacological tools. Biochem. Pharmacol. 2006, 71(4):399-407.
67. del Arco A., Morcillo J., Martínez-Morales J.R., Galián C., Martos V., Bovolenta P., et al. Expression of the aspartate/glutamate mitochondrial carriers aralar1 and citrin during development and in adult rat tissues. Eur. J. Biochem. 2002, 269(13):3313-3320.
68. +-regulated mitochondrial aspartate-glutamate carrier aralar1 in brain and prominent expression in the spinal cord. Brain Res. Dev. Brain Res. 2003, 143(1):33-46.
69. Jalil M.A., Begum L., Contreras L., Pardo B., Iijima M., Li M.X., et al. Reduced N-acetylaspartate levels in mice lacking aralar, a brain- and muscle-type mitochondrial aspartate-glutamate carrier. J. Biol. Chem. 2005, 280(35):31333-31339.
70. Pardo B., Rodrigues T.B., Contreras L., Garzón M., Llorente-Folch I., Kobayashi K., et al. Brain glutamine synthesis requires neuronal-born aspartate as amino donor for glial glutamate formation. J. Cereb. Blood Flow Metab. 2011, 31(1):90-101.
71. Brusilow S.W., Maestri N.E. Urea cycle disorders: diagnosis, pathophysiology, and therapy. Adv. Pediatr. 1996, 43:127-170.
72. Nakagawa T., Lomb D.J., Haigis M.C., Guarente L. SIRT5 deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. Cell 2009, 137(3):560-570.
73. Ogura M., Nakamura Y., Tanaka D., Zhuang X., Fujita Y., Obara A., et al. Overexpression of SIRT5 confirms its involvement in deacetylation and activation of carbamoyl phosphate synthetase 1. Biochem. Biophys. Res. Commun. 2010, 393(1):73-78.
74. Zhang L.Q., Heruth D.P., Ye S.Q. Nicotinamide phosphoribosyltransferase in human diseases. J. Bioanal. Biomed. 2011, 3:13-25.
75. Windmueller H.G., Spaeth A.E. Respiratory fuels and nitrogen metabolism in vivo in small intestine of fed rats. J. Biol. Chem. 1980, 255(1):107-112.
76. Souba W.W. Interorgan ammonia metabolism in health and disease: a surgeon's view. J. Parenter. Enteral Nutr. 1987, 11(6):569-579.
77. van de Poll M.C.G., Ligthart-Melis G.C., Boelens P.G., Deutz N.E.P., van Leeuwen P.A.M., Dejong C.H.C. Intestinal and hepatic metabolism of glutamine and citrulline in humans. J. Physiol. 2007, 581(2):819-827.
78. Bertolo R.F., Burrin D.G. Comparative aspects of tissue glutamine and proline metabolism. J. Nutr. 2008, 138(10):2032S-2039S.
79. Windmueller H.G., Spaeth A.E. Source and fate of circulating citrulline. Am. J. Physiol. 1981, 241(6):E473-E480.
80. 15N]glutamine. Role of pH, hormones and pyruvate. J. Biol. Chem. 1996, 271(49):31234-31242.
81. Osowska S., Moinard C., Loï C., Neveux N., Cynober L. Citrulline increases arginine pools and restores nitrogen balance after massive intestinal resection. Gut 2004, 53(12):1781-1786.
82. Cardona D.M., Zhang X., Liu C. Loss of carbamoyl phosphate synthetase 1 in small intestinal adenocarcinoma. Am. J. Clin. Pathol. 2009, 132(6):877-882.
83. Marini J.C. Arginine and ornithine are the main precursors for citrulline synthesis in mice. J. Nutr. 2012, 142(3):572-580.
84. Häussinger D. Nitrogen metabolism in liver: structural and functional organization and physiological relevance. Biochem. J. 1990, 267(2):281-290.
85. 13N]ammonia in rat liver in vivo. J. Biol. Chem. 1987, 262(3):1073-1080.
86. 13N as a tracer for studying glutamate metabolism. Neurochem. Int. 2011, 59(4):456-464.
87. 13N]ammonia in human and canine blood. J. Nucl. Med. 1990, 31(2):163-167.
88. Häussinger D. Hepatic glutamine metabolism. Beitr. Infusionther. Klin. Ernahr. 1987, 17:144-157.
89. Häussinger D., Gerok W. Hepatocyte heterogeneity in glutamate uptake by isolated perfused rat liver. Eur. J. Biochem. 1983, 136(2):421-425.
90. Lockwood A.H., Bolomey L., Napoleon F. Blood-brain barrier to ammonia in humans. J. Cereb. Blood Flow Metab. 1984, 4(4):516-522.
91. Sørensen M. Update on cerebral uptake of blood ammonia. Metab. Brain Dis. 2013, 28(2):155-159.
92. Behar K.L., Rothman D.L. In vivo nuclear magnetic resonance studies of glutamate-γ-aminobutyric acid-glutamine cycling in rodent and human cortex: the central role of glutamine. J. Nutr. 2001, 131(Suppl. 9):2498S-2504S.
93. Varoqui H., Zhu H., Yao D., Ming H., Erickson J.D. Cloning and functional identification of a neuronal glutamine transporter. J. Biol. Chem. 2000, 275(6):4049-4054.
94. + binding. J. Biol. Chem. 2009, 284(38):25823-25831.
95. Robinson B.H. Lactic acidemia: disorders of pyruvate carboxylase and pyruvate dehydrogenase. The Metabolic & Molecular Bases of Inherited Disease 2001, 2275-2295. McGraw-Hill, New York. eighth ed. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
96. Murin R., Cesar M., Kowtharapu B.S., Verleysdonk S., Hamprecht B. Expression of pyruvate carboxylase in cultured oligodendroglial, microglial and ependymal cells. Neurochem. Res. 2009, 34(3):480-489.
97. Hassel B., Bråthe A. Neuronal pyruvate carboxylation supports formation of transmitter glutamate. J. Neurosci. 2000, 20(4):1342-1347.
98. 13C NMR spectroscopy at 14.1T. Front. Neuroenergenetics 2011, 3:3.
99. Zwingmann C. The anaplerotic flux and ammonia detoxification in hepatic encephalopathy. Metab. Brain Dis. 2007, 22(3-4):235-249.
100. 13N-labeled ammonia in rat brain. J. Biol. Chem. 1979, 254(12):4982-4992.
101. Krivošíková Z., Spustová V., Dzúrik R. Participation of P-dependent and P-independent glutaminases in rat kidney ammoniagenesis and their modulation by metabolic acidosis, hippurate and insulin. Physiol. Res. 1998, 47(3):177-183.
102. Porter L.D., Ibrahim H., Taylor L., Curthoys N.P. Complexity and species variation of the kidney-type glutaminase gene. Physiol. Genomics 2002, 9(3):157-166.
103. Curthoys N.P., Kuhlenschmidt T. Phosphate-independent glutaminase from rat kidney. Partial purification and identity with gamma-glutamyltranspeptidase. J. Biol. Chem. 1975, 250(6):2099-2105.
104. Ambühl P.M., Amemiya M., Danczkay M., Lötscher M., Kaissling B., Moe O.W., et al. Chronic metabolic acidosis increases NHE3 protein abundance in rat kidney. Am. J. Physiol. 1996, 271(4 Pt. 2):F917-F925.
105. + exchanger 3: biphasic response and glucocorticoid dependence. Am. J. Physiol. Renal Physiol. 2002, 283(3):F532-F539.
106. Bourgeois S., Van Meer L., Wootla B., Bloch-Faure M., Chambrey R., Shull G.E., et al. NHE4 is critical for the renal handling of ammonia in rodents. J. Clin. Invest. 2010, 120(6):1895-1904.
107. Huber S., Asan E., Jöns T., Kerscher C., PÜschel B., Drenckhahn D. Expression of rat kidney anion exchanger 1 in type A intercalated cells in metabolic acidosis and alkalosis. Am. J. Physiol. Renal Physiol. 1999, 277(6 Pt. 2):F841-F849.
108. Quentin F., Eladari D., Cheval L., Lopez C., Goossens D., Colin Y., et al. RhBG and RhCG, the putative ammonia transporters, are expressed in the same cells in the distal nephron. J. Am. Soc. Nephrol. 2003, 14(3):545-554.
109. Brosnan M.E., Brosnan J.T. Orotic acid excretion and arginine metabolism. J. Nutr. 2007, 137(6 Suppl. 2):1656S-1661S.
110. Wu G., Knabe D.A., Flynn N.E. Synthesis of citrulline from glutamine in pig enterocytes. Biochem. J. 1994, 299(1):115-121.
111. Ratnakumari L., Qureshi I.A., Butterworth R.F. Evidence for cholinergic neuronal loss in brain in congenital ornithine transcarbamylase deficiency. Neurosci. Lett. 1994, 178(1):63-65.
112. Robinson M.B., Hopkins K., Batshaw M.L., McLaughlin B.A., Heyes M.P., Oster-Granite M.L. Evidence of excitotoxicity in the brain of the ornithine carbamoyltransferase deficient sparse fur mouse. Brain Res. Dev. Brain Res. 1995, 90(1-2):35-44.
113. Ratnakumari L., Qureshi I.A., Butterworth R.F. Central muscarinic M1 and M2 receptor changes in congenital ornithine transcarbamylase deficiency. Pediatr. Res. 1996, 40(1):25-28.
114. Lanpher B.C., Gropman A., Chapman K.A., Simpson K.L., Summar M.L. Urea cycle disorders overview. GeneReviews™ [Internet] 1993-2013, (2003 April, updated 2014 Sept. 11), University of Washington, Seattle, WA, Available from:, (accessed 06.10.14). http://www.ncbi.nlm.nih.gov/books/NBK1217/, R.A. Pagon, M.P. Adam, H.H. Ardinger (Eds.).
115. Häberle J., Boddaert N., Burlina A., Chakrapani A., Dixon M., Huemer M., et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J. Rare Dis. 2012, 7(1):32.
116. Senkevitch E., Cabrera-Luque J., Morizono H., Caldovic L., Tuchman M. A novel biochemically salvageable animal model of hyperammonemia devoid of N-acetylglutamate synthase. Mol. Genet. Metab. 2012, 106(2):160-168.
117. Wijburg F.A., Nassogne M.-C. Disorders of the urea cycle and related enzymes. Inborn Metabolic Diseases 2012, 297-310. Springer-Verlag, Berlin. fifth ed. J.-M. Saudubray, G. van den Berghe, J.H. Walter (Eds.).
118. Voorhies T.M., Ehrlich M.E., Duffy T.E., Petito C.K., Plum F. Acute hyperammonemia in the young primate: physiologic and neuropathologic correlates. Pediatr. Res. 1983, 17(12):970-975.
119. Wilcken B. Problems in the management of urea cycle disorders. Mol. Genet. Metab. 2004, 81(Suppl. 1):S86-S91.
120. Tuchman M., Lee B., Lichter-Konecki U., Summar M.L., Yudkoff M., Cederbaum S.D., et al. Cross-sectional multicenter study of patients with urea cycle disorders in the United States. Mol. Genet. Metab. 2008, 94(4):397-402.
121. Summar M., Tuchman M. Proceedings of a consensus conference for the management of patients with urea cycle disorders. J. Pediatr. 2001, 138(Suppl. 1):S6-S10.
122. Butterworth R.F. Effects of hyperammonaemia on brain function. J. Inherit. Metab. Dis. 1998, 21(Suppl. 1):6-20.
123. Braissant O. Current concepts in the pathogenesis of urea cycle disorders. Mol. Genet. Metab. 2010, 100(Suppl. 1):S3-S12.
124. Harding B.N., Surtees R.A.H. Metabolic and neurodegenerative diseases of childhood. Greenfield's Neuropathology 2008, 481-514. Hodder Arnold, London. eighth ed. S. Love, D.N. Louis, D.W. Ellison (Eds.).
125. Felipo V., Butterworth R.F. Neurobiology of ammonia. Prog. Neurobiol. 2002, 67(4):259-279.
126. Zwingmann C., Butterworth R. An update on the role of brain glutamine synthesis and its relation to cell-specific energy metabolism in the hyperammonemic brain: further studies using NMR spectroscopy. Neurochem. Int. 2005, 47(1-2):19-30.
127. Bosoi C.R., Rose C.F. Identifying the direct effects of ammonia on the brain. Metab. Brain Dis. 2009, 24(1):95-102.
128. Walker V. Ammonia toxicity and its prevention in inherited defects of the urea cycle. Diabetes Obes. Metab. 2009, 11(9):823-835.
129. Rama Rao K.V., Jayakumar A.R., Norenberg M.D. Glutamine in the pathogenesis of acute hepatic encephalopathy. Neurochem. Int. 2012, 61(4):575-580.
130. Seyan A.S., Hughes R.D., Shawcross D.L. Changing face of hepatic encephalopathy: role of inflammation and oxidative stress. World J. Gastroenterol. 2010, 16(27):3347-3357.
131. Cooper A.J.L. Possible treatment of end-stage hyperammonemic encephalopathy by inhibition of glutamine synthetase. Metab. Brain Dis. 2013, 28(2):119-125.
132. Kimelberg H.K., Macvicar B.A., Sontheimer H. Anion channels in astrocytes. Glia 2006, 54(7):747-757.
133. Farrell D.J., Bower L. Fatal water intoxication. J. Clin. Pathol. 2003, 56(10):803-804.
134. Kelly T., Rose C.R. Ammonium influx pathways into astrocytes and neurones of hippocampal slices. J. Neurochem. 2010, 115(5):1123-1136.
135. Jayakamur A.R., Liu M., Moriyama M., Ramakrishnan R., Forbush B., Reddy P.V.B., et al. Na-K-Cl cotransporter-1 in the mechanism of ammonia-induced astrocyte swelling. J. Biol. Chem. 2008, 283(49):33874-33882.
136. + exchanger isoform 1 null mice. Am. J. Physiol. Cell Physiol. 2004, 287(1):C12-C21.
137. Albrecht J., Norenberg M.D. Glutamine: a Trojan horse in ammonia neurotoxicity. Hepatology 2006, 44(4):788-794.
138. Bosoi C.R., Zwingmann C., Marin H., Parent-Robitaille C., Huynh J., Tremblay M., et al. Increased brain lactate is central to the development of brain edema in rats with chronic liver disease. J. Hepatol. 2014, 60(3):554-560.
139. Oria M., Jalan R. Brain lactate in hepatic encephalopathy: friend or foe?. J. Hepatol. 2014, 60(3):476-477.
140. Shawcross D.L., Balata S., Olde Damink S.W.M., Hayes P.C., Wardlaw J., Marshall I., et al. Low myo-inositol and high glutamine levels in brain are associated with neuropsychological deterioration after induced hyperammonemia. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 287(3):G503-G509.
141. A-or sigma receptors in cerebellum in vivo. J. Neurochem. 2013, 125(1):133-143.
142. Cichoz-Lach H., Michalak A. Current pathogenetic aspects of hepatic encephalopathy and noncirrhotic hyperammonemic encephalopathy. World J. Gastroenterol. 2013, 19(1):26-34.
143. Basile A.S., Jones E.A. Ammonia and GABA-ergic neurotransmission: interrelated factors in the pathogenesis of hepatic encephalopathy. Hepatology 1997, 25(6):1303-1305.
144. Jones E.A. Ammonia, the GABA neurotransmitter system, and hepatic encephalopathy. Metab. Brain Dis. 2002, 17(4):275-281.
145. A receptor complex by ammonia: implications for the pathogenesis of hyperammonemic syndromes. Brain Res. 1996, 720(1-2):35-44.
146. Ahboucha S., Araqi F., Layrargues G.P., Butterworth R.F. Differential effects of ammonia on the benzodiazepine modulatory site on the GABA-A receptor complex of human brain. Neurochem. Int. 2005, 47(1-2):58-63.
147. Cagnin A., Taylor-Robinson S.D., Forton D.M., Banati R.B. In vivo imaging of cerebral "peripheral benzodiazepine binding sites" in patients with hepatic encephalopathy. Gut 2006, 55(4):547-553.
148. Desjardins P., Butterworth R.F. The "peripheral-type" benzodiazepine (omega 3) receptor in hyperammonemic disorders. Neurochem. Int. 2002, 41(2-3):109-114.
149. Mukhin A.G., Papadopoulos V., Costa E., Krueger K.E. Mitochondrial benzodiazepine receptors regulate steroid biosynthesis. Proc. Natl. Acad. Sci. U.S.A. 1989, 86(24):9813-9816.
150. Papadopoulos V., Lecanu L., Brown R.C., Han Z., Yao Z.-X. Peripheral-type benzodiazepine receptor in neurosteroid biosynthesis, neuropathology and neurological disorders. Neuroscience 2006, 138(3):749-756.
151. García-Ayllón M.-S., Cauli O., Silveyra M.-X., Rodrigo R., Candela A., Compañ A., et al. Brain cholinergic impairment in liver failure. Brain 2008, 131(11):2946-2956.
152. Hindfelt B., Plum F., Duffy T.E. Effect of acute ammonia intoxication on cerebral metabolism in rats with portacaval shunts. J. Clin. Invest. 1977, 59(3):386-396.
153. Rama Rao K.V., Norenberg M.D. Brain energy metabolism and mitochondrial dysfunction in acute and chronic hepatic encephalopathy. Neurochem. Int. 2012, 60(7):697-706.
154. Lockwood A.H., Yap E.W.H., Rhoades H.M., Wang W.H. Altered cerebral blood flow and glucose metabolism in patients with liver disease and minimal encephalopathy. J Cereb. Blood Flow Metab. 1991, 11(2):331-336.
155. Weissenborn K., Bokemeyer M., Ahl B., Fischer-Wasels D., Giewekemeyer K., van den Hoff J. Functional imaging of the brain in patients with liver cirrhosis. Metab. Brain Dis. 2004, 19(3-4):269-280.
156. Lai J.C., Cooper A.J. Brain alpha-ketoglutarate dehydrogenase complex: kinetic properties, regional distribution, and effects of inhibitors. J. Neurochem. 1986, 47(5):1376-1386.
157. Murthy C.R., Rama Rao K.V., Bai G., Norenberg M.D. Ammonia-induced production of free radicals in primary cultures of rat astrocytes. J. Neurosci. Res. 2001, 66(2):282-288.
158. Jayakumar A.R., Rama Rao K.V., Schousboe A., Norenberg M.D. Glutamine-induced free radical production in cultured astrocytes. Glia 2004, 46(3):296-301.
159. Kosenko E., Kaminsky Y., Kaminsky A., Valencia M., Lee L., Hermenegildo C., et al. Superoxide production and antioxidant enzymes in ammonia intoxication in rats. Free Radic. Res. 1997, 27(6):637-644.
160. Kosenko E., Venediktova N., Kaminsky Y., Montoliu C., Felipo V. Sources of oxygen radicals in brain in acute ammonia intoxication in vivo. Brain Res. 2003, 981(1-2):193-200.
161. Sathyasaikumar K.V., Swapna I., Reddy P.V., Murthy Ch.R., Dutta Gupta A., Senthilkumaran B., et al. Fulminant hepatic failure in rats induces oxidative stress differentially in cerebral cortex, cerebellum and pons medulla. Neurochem. Res. 2007, 32(3):517-524.
162. Jayakumar A.R., Panickar K.S., Murthy Ch.R.K., Norenberg M.D. Oxidative stress and mitogen-activated protein kinase phosphorylation mediate ammonia-induced cell swelling and glutamate uptake inhibition in cultured astrocytes. J. Neurosci. 2006, 26(18):4774-4784.
163. Detry O., De Roover A., Honoré P., Meurisse M. Brain edema and intracranial hypertension in fulminant hepatic failure: pathophysiology and management. World J. Gastroenterol. 2006, 12(46):7405-7412.
164. Gjedde A., Lockwood A.H., Duffy T.E., Plum F. Cerebral blood flow and metabolism in chronically hyperammonemic rats: effect of an acute ammonia challenge. Ann. Neurol. 1978, 3(4):325-330.
165. Lockwood A.H., Ginsberg M.D., Rhoades H.M., Gutierrez M.T. Cerebral glucose metabolism after portacaval shunting in the rat. Patterns of metabolism and implications for the pathogenesis of hepatic encephalopathy. J. Clin. Invest. 1986, 78(1):86-95.
166. O'Carroll R.E., Ebmeier K.P., Dougall N., Murray C., Goodwin G.M., Hayes P.C., et al. Regional cerebral blood flow and cognitive function in patients with chronic liver disease. Lancet 1991, 337(8752):1250-1253.
167. Kofuji P., Newman E.A. Potassium buffering in the central nervous system. Neuroscience 2004, 129(4):1045-1056.
168. Sugimoto H., Koehler R.C., Wilson D.A., Brusilow S.W., Traystman R.J. Methionine sulfoximine, a glutamine synthetase inhibitor, attenuates increased extracellular potassium activity during acute hyperammonemia. J. Cereb. Blood Flow Metab. 1997, 17(1):44-49.
169. De Meirleir L.J., Brivet M., Garcia-Cazorla A. Disorders of pyruvate metabolism and the tricarboxylic acid cycle. Inborn Metabolic Diseases 2012, 187-200. Springer-Verlag, Berlin. fifth ed. J.-M. Saudubray, G. van den Berghe, J.H. Walter (Eds.).
170. Nicolao F., Efrati C., Masini A., Merli M., Attili A.F., Riggio O. Role of determination of partial pressure of ammonia in cirrhotic patients with and without hepatic encephalopathy. J. Hepatol. 2003, 38(4):441-446.
171. Evans D.R., Guy H.I. Mammalian pyrimidine biosynthesis: fresh insights into an ancient pathway. J. Biol. Chem. 2004, 279(32):33035-33038.
172. Monks A., Chisena C.A., Cysyk R.L. Influence of ammonium ions on hepatic de novo pyrimidine biosynthesis. Arch. Biochem. Biophys. 1985, 236(1):1-10.
173. Kuhara T., Inoue Y., Ohse M., Krasnikov B.F., Cooper A.J.L. Urinary 2-hydroxy-5-oxoproline, the lactam form of α-ketoglutaramate, is markedly increased in urea cycle disorders. Anal. Bioanal. Chem. 2011, 400(7):1843-1851.
174. Halámková L., Mailloux S., Halámek J., Cooper A.J.L., Katz E. Enzymatic analysis of α-ketoglutaramate-a biomarker for hyperammonemia. Talanta 2012, 100C:7-11.
175. The Urea Cycle Disorders Conference Group Consensus statement from a conference for the management of patients with urea cycle disorders. J. Pediatr. 2001, 138(Suppl. 1):S1-S5.
176. Nassogne M.C., Héron B., Touati G., Rabier D., Saudubray J.-M. Urea cycle defects: management and outcome. J. Inherit. Metab. Dis. 2005, 28(3):407-414.
177. Summar M.L., Dobbelaere D., Brusilow S., Lee B. Diagnosis, symptoms, frequency and mortality of 260 patients with urea cycle disorders from a 21-year, multicentre study of acute hyperammonaemic episodes. Acta Paediatr. 2008, 97(10):1420-1425.
178. The National Organization for Rare Disorders The physician's guide to urea cycle disorders (accessed 21.05.14). http://www.nordphysicianguides.org/urea-cycle-disorders/.
179. Wong D., Cederbaum S., Crombez E.A. Arginase Deficiency. GeneReviews™ [Internet] 1993-2013, (2004 October 21, updated 2014 August 28), University of Washington, Seattle, WA, Available from:, (accessed 07.10.14). http://www.ncbi.nlm.nih.gov/books/NBK1159/, R.A. Pagon, M.P. Adam, H.H. Ardinger (Eds.).
180. C.L. Kniffin, Argininemia, OMIM Entry 20780, 2010 (accessed 07.10.14). http://omim.org/entry/207800.
181. Yamaguchi S., Brailey L.L., Morizono H., Bale A.E., Tuchman M. Mutations and polymorphisms in the human ornithine transcarbamylase (OTC) gene. Hum. Mutat. 2006, 27(7):626-632.
182. Maestri N.E., Lord C., Glynn M., Bale A., Brusilow S.W. The phenotype of ostensibly healthy women who are carriers for ornithine transcarbamylase deficiency. Medicine (Baltimore) 1998, 77(6):389-397.
183. Gyato K., Wray J., Huang Z.J., Yudkoff M., Batshaw M.L. Metabolic and neuropsychological phenotype in women heterozygous for ornithine transcarbamylase deficiency. Ann. Neurol. 2004, 55(1):80-86.
184. Uchino T., Endo F., Matsuda I. Neurodevelopmental outcome of long-term therapy of urea cycle disorders in Japan. J. Inherit. Metab. Dis. 1998, 21(Suppl. 1):151-159.
185. Enns G.M., Berry S.A., Berry G.T., Rhead W.J., Brusilow S.W., Hamosh A. Survival after treatment with phenylacetate and benzoate for urea-cycle disorders. N. Engl. J. Med. 2007, 356:2282-2292.
186. Sebastio G., Nunes V. Lysinuric Protein Intolerance. GeneReviews™ [Internet] 1993-2013, (2006 December, updated 2011 October), University of Washington, Seattle, WA, (accessed 07.10.14). http://www.ncbi.nlm.nih.gov/books/NBK1361/, R.A. Pagon, M.P. Adam, H.H. Ardinger (Eds.).
187. +L activity is defective in monocytes and in GM-CSF-differentiated macrophages. Orphanet J. Rare Dis. 2010, 5:32.
188. Tanner L., Näntö-Salonen K., Niinikoski H., Erkkola R., Huoponen K., Simmell O. Hazards associated with pregnancies and deliveries in lysinuric protein intolerance. Metabolism 2006, 55(2):224-231.
189. British Inherited Metabolic Disease Group, Guidelines, BIMDG Emergency Protocols. Adult Emergency Management: Urea Cycle Defects (2012). , 2012 (accessed 07.10.14). http://www.bimdg.org.uk/guidelines.asp.
190. Berry G.T., Steiner D. Long-term management of patients with urea cycle disorders. J. Pediatr. 2001, 138(Suppl. 1):S56-S61.
191. Leonard J.V. The nutritional management of urea cycle disorders. J. Pediatr. 2001, 138(Suppl. 1):S40-S45.
192. Australasian Society for Inborn Errors of Metabolism, Human Genetics Society of Australasia, The ASIEM Low Protein Handbook for Urea Cycle Disorders, Sections 1.1-1.17, 2007 (accessed 07.10.14). http://www.hgsa.org.au/documents/item/47.
193. Moriyama M., Li M.X., Kobayashi K., Sinasac D.S., Kannan Y., Iijima M., et al. Pyruvate ameliorates the defect in ureogenesis from ammonia in citrin-deficient mice. J. Hepatol. 2006, 44(5):930-938.
194. Yazaki M., Ikeda S., Kobayashi K., Saheki T. Therapeutic approaches for patients with adult-onset type II citrullinemia (CTLN2): effectiveness of treatment with low-carbohydrate diet and sodium pyruvate. Rinsho Shinkeigaku 2010, 50(11):844-847.
195. Batshaw M.L., MacArthur R.B., Tuchman M. Alternative pathway therapy for urea cycle disorders: twenty years later. J. Pediatr. 2001, 138(Suppl. 1):S46-S55.
196. Barshop B.A., Breuer J., Holm J., Leslie J., Nyhan W.L. Excretion of hippuric acid during sodium benzoate therapy in patients with hyperglycinaemia or hyperammonaemia. J. Inherit. Metab. Dis. 1989, 12(1):72-79.
197. Smith W., Diaz G.A., Lichter-Konecki U., Berry S.A., Harding C.O., McCandless S.E., et al. Ammonia control in children ages 2 months through 5 years with urea cycle disorders: comparison of sodium phenylbutyrate and glycerol phenylbutyrate. J. Paediatr. 2013, 162(6):1228-1234.
198. Praphanphoj V., Boyadjiev S.A., Waber L.J., Brusilow S.W., Geraghty M.T. Three cases of intravenous sodium benzoate and sodium phenylacetate toxicity occurring in the treatment of acute hyperammonaemia. J. Inherit. Metab. Dis. 2000, 23(2):129-136.
199. Leonard J.V., McKiernan P.J. The role of liver transplantation in urea cycle disorders. Mol. Genet. Metab. 2004, 81(Suppl. 1):S74-S78.
200. Meyburg J., Das A.M., Hoerster F., Lindner M., Kriegbaum H., Engelmann G., et al. One liver for four children: first clinical series of liver transplantation for severe neonatal urea cycle defects. Transplantation 2009, 87(5):636-641.
201. Editorial, Gene therapy-a loss of innocence, Nat. Med. 6 (1) (2000) 1.
202. Alexander I.E., Kok C., Dane A.P., Cunningham S.C. Gene therapy for metabolic disorders: an overview with a focus on urea cycle disorders. J. Inherit. Metab. Dis. 2012, 35(4):641-645.
203. Vockley J., Ensenauer R. Isovaleric acidemia: new aspects of genetic and phenotypic heterogeneity. Am. J. Med. Genet. C Semin. Med. Genet. 2006, 142C(2):95-103.
204. Brown G.K., Scholem R.D., Hunt S.M., Harrison J.R., Pollard A.C. Hyperammonaemia and lactic acidosis in a patient with pyruvate dehydrogenase deficiency. J. Inherit. Metab. Dis. 1987, 10(4):359-366.
205. Wanders R.J.A., Vreken P., den Boer M.E.J., Wijburg F.A., van Gennip A.H., IJIst L. Disorders of mitochondrial fatty acyl-CoA β-oxidation. J. Inherit. Metab. Dis. 1999, 22(4):442-487.
206. Longo N., di San Filippo C.A., Pasquali M. Disorders of carnitine transport and the carnitine cycle. Am. J. Med. Genet. C Semin. Med. Genet. 2006, 142C(2):77-85.
207. Angelini C., Federico A., Reichmann H., Lombes A., Chinnery P., Turnbull D. Task force guidelines handbook: EFNS guidelines on diagnosis and management of fatty acid mitochondrial disorders. Eur. J. Neurol. 2006, 13(9):923-929.
208. Ahmad A., Kahler S.G., Kishnani P.S., Artigas-Lopez M., Pappu A.S., Steiner R., et al. Treatment of pyruvate carboxylase deficiency with high doses of citrate and aspartate. Am. J. Med. Genet. 1999, 87(4):331-338.
209. Roe C.R., Mochel F. Anaplerotic diet therapy in inherited metabolic disease: therapeutic potential. J. Inherit. Metab. Dis. 2006, 29(2-3):332-340.
210. Breen C., White F.J., Scott C.A.B., Hepinstall L., Walter J.H., Jones S.A., et al. Unsuccessful treatment of severe pyruvate carboxylase deficiency with triheptanoin. Eur. J. Pediatr. 2014, 173(3):361-366.
211. Borges K., Sonnewald U. Triheptanoin-a medium chain triglyceride with odd chain fatty acids: a new anaplerotic anticonvulsant treatment?. Epilepsy Res. 2012, 100(3):239-244.
212. Stanley C.A., Lieu Y.K., Hsu B.Y.L., Burlina A.B., Greenberg C.R., Hopwood N.J., et al. Hyperinsulinism and hyperammonemia in infants with regulatory mutations of the glutamate dehydrogenase gene. N. Engl. J. Med. 1998, 338(19):1352-1357.
213. de Lonlay P., Benelli C., Fouque F., Ganguly A., Aral B., Dionisi-Vici C., et al. Hyperinsulinism and hyperammonemia syndrome: report of twelve unrelated patients. Pediatr. Res. 2001, 50(3):353-357.
214. Kapoor R.R., Flanagan S.E., Fulton P., Chakrapani A., Chadefaux B., Ben-Omran T., et al. Hyperinsulinism-hyperammonaemia syndrome: novel mutations in the GLUD1 gene and genotype-phenotype correlations. Eur. J. Endocrinol. 2009, 161(5):731-735.
215. Palladino A.A., Stanley C.A. The hyperinsulinism/hyperammonemia syndrome. Rev. Endocr. Metab. Disord. 2010, 11(3):171-178.
216. Zammarchi E., Filippi L., Novembre E., Donati M.A. Biochemical evaluation of a patient with a familial form of leucine-sensitive hypoglycaemia and concomitant hyperammonemia. Metabolism 1996, 45(8):957-960.
217. Huijmans J.G.M., Duran M., de Klerk J.B.C., Rovers M.J., Scholte H.R. Functional hyperactivity of hepatic glutamate dehydrogenase as a cause of the hyperinsulinism/hyperammonemia syndrome: effect of treatment. Pediatrics 2000, 106(3):596-600.
218. Treberg J.R., Clow K.A., Greene K.A., Brosnan M.E., Brosnan J.T. Systemic activation of glutamate dehydrogenase increases renal ammoniagenesis: implications for the hyperinsulinism/hyperammonemia syndrome. Am. J. Physiol. Endocrinol. Metab. 2010, 298(6):E1219-E1225.
219. Chaussain J.L., Georges P., Gendrel D., Donnadieu M., Job J.C. Serum branched-chain amino acids in the diagnosis of hyperinsulinism in infancy. J. Pediatr. 1980, 97(6):923-926.
220. Häberle J., Görg B., Rutsch F., Schmidt E., Toutain A., Benoist J.-F., et al. Congenital glutamine deficiency with glutamine synthetase mutations. N. Engl. J. Med. 2005, 353(18):1926-1933.
221. Häberle J., Shahbeck N., Ibrahim K., Schmitt B., Scheer I., O'Gorman R., et al. Glutamine supplementation in a child with inherited GS deficiency improves the clinical status and partially corrects the peripheral and central amino acid imbalance. Orphanet J. Rare Dis. 2012, 7:48.
222. National Institutes of Health, Fluoruracil-Liver Tox, 2013 (accessed 07.10.14). http://www.livertox.nih.gov/Fluorouracil.htm.
223. Kim S.-R., Park C.-H., Park S., Park J.-O., Lee J., Lee S.-Y. Genetic polymorphisms associated with 5-fluorouracil-induced neurotoxicity. Chemotherapy 2010, 56(4):313-317.
224. Baumgartner M.R., Rabier D., Nassogne M.-C., Dufier J.-L., Padovani J.-P., Kamoun P., et al. Delta 1-pyrroline-5-carboxylate synthase deficiency: neurodegeneration, cataracts and connective tissue manifestations combined with hyperammonaemia and reduced ornithine, citrulline, arginine and proline. Eur. J. Pediatr. 2005, 164(1):31-36.
225. Martinelli D., Häberle J., Rubio V., Giunta C., Hausser I., Carrozzo R., et al. Understanding pyrroline-5-carboxylate synthetase deficiency: clinical, molecular, functional, and expression studies, structure-based analysis, and novel therapy with arginine. J. Inherit. Metab. Dis. 2012, 35(5):761-776.
226. Ferenci P., Lockwood A., Mullen K., Tarter R., Weissenborn K., Blei A.T., et al. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002, 35(3):716-721.
227. Bhatia V., Singh R., Acharya S.K. Predictive value of arterial ammonia for complications and outcome in acute liver failure. Gut 2006, 55(1):98-104.
228. Wakim-Fleming J. Hepatic encephalopathy: suspect it early in patients with cirrhosis. Cleve. Clin. J. Med. 2011, 78(9):597-605.
229. Olde Damink S.W.M., Jalan R., Dejong C.H.C. Interorgan ammonia trafficking in liver disease. Metab. Brain Dis. 2009, 24(1):169-181.
230. Butterworth R.F. Hepatic encephalopathy: a central neuroinflammatory disorder?. Hepatology 2011, 53(4):1372-1376.
231. Brusilow S.W., Cooper A.J.L. Encephalopathy in acute liver failure resulting from acetaminophen intoxication: new observations with potential therapy. Crit. Care Med. 2011, 39(11):2550-2553.
232. Wright G., Noiret L., Olde Damink S.W.M., Jalan R. Interorgan ammonia metabolism in liver failure: the basis of current and future therapies. Liver Int. 2011, 31(2):163-175.
233. Keiding S., Pavese N. Brain metabolism in patients with hepatic encephalopathy studied by PET and MR. Arch. Biochem. Biophys. 2013, 536(2):131-142.
234. Lavoie J., Giguère J.-F., Layrargues G.P., Butterworth R.F. Amino acid changes in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. J. Neurochem. 1987, 49(3):692-697.
235. Balata S., Olde Damink S.W.M., Ferguson K., Marshall I., Hayes P.C., Deutz N.E.P., et al. Induced hyperammonemia alters neuropsychology, brain MR spectroscopy and magnetization transfer in cirrhosis. Hepatology 2003, 37(4):931-939.
236. Clemmesen J.O., Larsen F.S., Kondrup J., Hansen B.A., Ott P. Cerebral herniation in patients with acute E liver failure is correlated with arterial ammonia concentration. Hepatology 1999, 29(3):648-653.
237. Olde-Damink S.W.M., Jalan R., Deutz N.E.P., Redhead D.N., Dejong C.H.C., Hynd P., et al. The kidney plays a major role in the hyperammonemia seen after simulated or actual GI bleeding in patients with cirrhosis. Hepatology 2003, 37(6):1277-1285.
238. Ytrebø L.M., Sen S., Rose C., Ten Have G.A.M., Davies N.A., Hodges S., et al. Interorgan ammonia, glutamate, and glutamine trafficking in pigs with acute liver failure. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 291(3):G373-G381.
239. Lockwood A.H., McDonald J.M., Reiman R.E., Gelbard A.S., Laughlin J.S., Duffy T.E., et al. The dynamics of ammonia metabolism in man. J. Clin. Invest. 1979, 63(3):449-460.
240. Dejong C.H.C., Deutz N.E.P., Soeters P.B. Muscle ammonia and glutamine exchange during chronic liver insufficiency in the rat. J. Hepatol. 1994, 21(3):299-307.
241. Clemmesen J.O., Kondrup J., Ott P. Splanchnic and leg exchange of amino acids and ammonia in acute liver failure. Gastroenterology 2000, 118(6):1131-1139.
242. Shimamoto C., Hirata I., Katsu K. Breath and blood ammonia in liver cirrhosis. Hepatogastroenterology 2000, 47(32):443-445.
243. Dejong C.H., Deutz N.E., Soeters P.B. Renal ammonia and glutamine metabolism during liver insufficiency-induced hyperammonemia in the rat. J. Clin. Invest. 1993, 92(6):2834-2840.
244. Dejong C.H.C., Deutz N.E.P., Soeters P.B. Metabolic adaptation of the kidney to hyperammonemia during chronic liver insufficiency in the rat. Hepatology 1993, 18(4):890-902.
245. Blei A.T., Córdoba J., The Practice Parameters Committee of the American College of Gastroenterology Practice guidelines hepatic encephalopathy. Am. J. Gastroenterol. 2001, 96(7):1968-1976.
246. Misel M.L., Gish R.G., Patton H., Mendler M. Sodium benzoate for treatment of hepatic encephalopathy. Gastroenterol. Hepatol. 2013, 9(4):219-227.
247. Sushma S., Dasarathy S., Tandon R.K., Jain S., Gupta S., Bhist M.S. Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial. Hepatology 1992, 16(1):138-144.
248. Rockey D.C., Vierling J.M., Mantry P., Ghabril M., Brown R.S., Alexeeva O., et al. Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology 2014, 59(3):1073-1083.
249. McGuire B.M., Zupanets I.A., Lowe M.E., Xiao X., Syplyviy V.A., Monteleone J., et al. Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosis. Hepatology 2010, 51(6):2077-2085.
250. Kircheis G., Nilius R., Held C., Berndt H., Buchner M., Görtelmeyer R., et al. Therapeutic efficacy of l-ornithine-l-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology 1997, 25(6):1351-1360.
251. de Soárez P.C., Oliveira A.C., Padovan J., Parise E.R., Ferraz M.B. A critical analysis of studies assessing l-ornithine-l-aspartate (LOLA) in hepatic encephalopathy treatment. Arq. Gastroenterol. 2009, 46(3):241-247.
252. Acharya S.K., Bhatia V., Sreenivas V., Khanal S., Panda S.K. Efficacy of l-ornithine l-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study. Gastroenterology 2009, 136(7):2159-2168.
253. Jalan R., Wright G., Davies N.A., Hodges S.J. l-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy. Med. Hypotheses 2007, 69(5):1064-1069.
254. Davies N.A., Wright G., Ytrebø L.M., Stadlbauer V., Fuskevåg O.-M., Zwingmann C., et al. l-Ornithine and phenylacetate synergistically produce sustained reduction in ammonia and brain water in cirrhotic rats. Hepatology 2009, 50(1):155-164.
255. Ytrebø L.M., Kristiansen R.G., Maehre H., Fuskevåg O.M., Kalsted T., Revhaug A., et al. l-Ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure. Hepatology 2009, 50(1):165-174.
256. Dadsetan S., Sørensen M., Bak L.K., Vilstrup H., Ott P., Schousboe A., et al. Interorgan metabolism of ornithine phenylacetate (OP)-a novel strategy for treatment of hyperammonemia. Biochem. Pharmacol. 2013, 85(1):115-123.
257. Chatauret N., Zwingmann C., Rose C., Leibfritz D., Butterworth R.F. Effects of hypothermia on brain glucose metabolism in acute liver failure: a H/C-nuclear magnetic resonance study. Gastroenterology 2003, 125(3):815-824.
258. Vogels B.A.P.M., Maas M.A.W., Daalhuisen J., Quack G., Chamuleau R.A.F.M. Memantine, a noncompetative NMDA receptor antagonist improves hyperammonemia-induced encephalopathy and acute hepatic encephalopathy in rats. Hepatology 1997, 25(4):820-827.
259. Orgogozo J.-M., Rigaud A.-S., Stöffler A., Möbius H.-J., Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM30). Stroke 2002, 33(7):1834-1839.
260. National Institute of Health, Memantine (2014), last updated 10.09.14 (accessed 08.10.14). http://www.livertox.nlm.nih.gov/Memantine.htm.
261. Jiang W., Desjardins P., Butterworth R.F. Minocycline attenuates oxidative/nitrosative stress and cerebral complications of acute liver failure in rats. Neurochem. Int. 2009, 55(7):601-605.
262. Goldstein N.S., Bayati N., Silverman A.L., Gordon S.C. Minocycline as a cause of drug-induced autoimmune hepatitis. Am. J. Clin. Pathol. 2000, 114(4):591-598.
263. Master S., Gottstein J., Blei A.T. Cerebral blood flow and the development of ammonia-induced brain edema in rats after portacaval anastomosis. Hepatology 1999, 30(4):876-880.
264. Goulenok C., Bernard B., Cadranel J.F., Thabut D., Di Martino V., Opolon P., et al. Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis. Aliment. Pharmacol. Ther. 2002, 16(3):361-372.
265. Erceg S., Monfort P., Hernández-Viadel M., Rodrigo R., Montoliu C., Felipo V. Oral administration of sildenafil restores learning ability in rats with hyperammonemia and with portacaval shunts. Hepatology 2005, 41(2):299-306.
266. Yurdaydin C., Herneth A.M., Püspök A., Steindl P., Singer E., Ferenci P. Modulation of hepatic encephalopathy in rats with thioacetamide-induced acute liver failure by serotonin. Eur. J. Gastroenterol. Hepatol. 1996, 8(7):667-671.
267. DeWolfe J.L., Knowlton R.C., Beasley M.T., Cofield S., Faught E., Limdi N.A. Hyperammonemia following intravenous valproate loading. Epilepsy Res. 2009, 85(1):65-71.
268. Wadzinski J., Franks R., Roane D., Bayard M. Valproate-associated hyperammonemic encephalopathy. J. Am. Board Fam. Med. 2007, 20(5):499-502.
269. Segura-Bruna N., Rodriguez-Campello A., Puente V., Roquer J. Valproate-induced hyperammonemic encephalopathy. Acta Neurol. Scand. 2006, 114(1):1-7.
270. 1H-MRS. Epilepsia 2009, 50(3):486-492.
271. Kaveggia F.F., Thompson J.S., Schafer E.C., Fischer J.L., Taylor R.J. Hyperammonemic encephalopathy in urinary diversion with urea-splitting urinary tract infection. Arch. Intern. Med. 1990, 150(11):2389-2392.
272. Koch M.O., McDougal W.S. The pathophysiology of hyperchloremic metabolic acidosis after urinary diversion through intestinal segments. Surgery 1985, 98(3):561-570.
273. Hawkes N.D., Thomas G.A.O., Jurewicz A., Williams O.M., Hillier C.E.M., McQueen I.N.F., et al. Non-hepatic hyperammonaemia: an important, potentially reversible cause of encephalopathy. Postgrad. Med. J. 2001, 77(913):717-722.
274. Hudak M.L., Jones M.D., Brusilow S.W. Differentiation of transient hyperammonemia of the newborn and urea cycle enzyme defects by clinical presentation. J. Pediatr. 1985, 107(5):712-719.
275. Lora-Tamayo J., Palom X., Sarrá J., Gasch O., Isern V., Fernández de Sevilla A., et al. Multiple myeloma and hyperammonemic encephalopathy: review of 27 cases. Clin. Lymphoma Myeloma 2008, 8(6):363-369.
276. Watson A.J., Karp J.E., Walker W.G., Chambers T., Risch V.R., Brusilow S.W. Transient idiopathic hyperammonaemia in adults. Lancet 1985, 326(8467):1271-1274.
277. Nott L., Price T.J., Pittman K., Patterson K., Fletcher J. Hyperammonemia encephalopathy: an important cause of neurological deterioration following chemotherapy. Leuk. Lymphoma 2007, 48(9):1702-1711.
278. Jörck C., Kiess W., Weigel J.F.W., Mütze U., Bierbach U., Beblo S. Transient hyperammonemia due to l-asparaginase therapy in children with acute lymphoblastic leukaemia or non-Hodgkin lymphoma. Pediatr. Hematol. Oncol. 2011, 28(1):3-9.
279. Adams E.N., Marks A., Lizer M.H. Carbamazepine-induced hyperammonemia. Am. J. Health Syst. Pharm. 2009, 66(16):1468-1470.
280. Hall S.M. Reye's syndrome and aspirin: a review. J. R. Soc. Med. 1986, 79(10):596-598.
281. Orlowski J.P. Whatever happened to Reye's syndrome? Did it ever really exist?. Crit. Care Med. 1999, 27(8):1582-1587.
282. Deschamps D., Fisch C., Fromenty B., Berson A., Degott C., Pessayre D. Inhibition by salicylic acid of the activation and thus oxidation of long chain fatty acids. Possible role in the development of Reye's syndrome. J. Pharmacol. Exp. Ther. 1991, 259(2):894-904.
283. Glasgow J.F.T., Middleton B., Moore R., Gray A., Hill J. The mechanism of inhibition of β-oxidation by aspirin metabolites in skin fibroblasts from Reye's syndrome patients and controls. Biochim. Biophys. Acta-Molecular Basis of Disease 1999, 1454(1):115-125.
284. Battaglia V., Salvi M., Toninello A. Oxidative stress is responsible for mitochondrial permeability transition induction by salicylate in liver mitochondria. J. Biol. Chem. 2005, 280(40):33864-33872.
285. Pita A.M., Fernandez-Bustos A., Rodes M., Arranz J.A., Fisac C., Virgili N., et al. Orotic aciduria and plasma urea-cycle-related amino acid alterations in short bowel syndrome, evoked by an arginine-free diet. J. Parenter. Enteral Nutr. 2004, 28(5):315-323.
286. Clay A.S., Hainline B.E. Hyperammonemia in the ICU. Chest 2007, 132(4):1368-1378.
287. Hamilton Stewart P.A., Barlow I.M. Metabolic effects of prostatectomy. J. R. Soc. Med. 1989, 82(12):725-728.
288. Thobe N., Pilger P., Jones M.P. Primary hypothyroidism masquerading as hepatic encephalopathy: case report and review of the literature. Postgrad. Med. J. 2000, 76(897):424-426.
289. Rimar D., Kruzel-Davila E., Dori G., Baron E., Bitterman H. Hyperammonemic coma-barking up the wrong tree. J. Gen. Intern. Med. 2007, 22(4):549-552.